Literature DB >> 27743577

Decade-Long Trends (2001 to 2011) in the Use of Evidence-Based Medical Therapies at the Time of Hospital Discharge for Patients Surviving Acute Myocardial Infarction.

Raghavendra Charan P Makam1, Nathaniel Erskine1, David D McManus2, Darleen Lessard1, Joel M Gore2, Jorge Yarzebski1, Robert J Goldberg3.   

Abstract

Optimization of medical therapy during discharge planning is vital for improving patient outcomes after hospitalization for acute myocardial infarction (AMI). However, limited information is available about recent trends in the prescribing of evidence-based medical therapies in these patients, especially from a population-based perspective. We describe decade-long trends in the discharge prescribing of aspirin, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, β blockers, and statins in hospital survivors of AMI. The study population consisted of 5,253 patients who were discharged from all 11 hospitals in central Massachusetts after AMI in 6 biennial periods from 2001 to 2011. Combination medical therapy (CMT) was defined as the prescription of all 4 cardiac medications at hospital discharge. The average age of this patient population was 69.2 years and 57.7% were men. Significant increases were observed in the use of CMT, from 25.6% in 2001 to 48.7% in 2011, with increases noted for each of the individual cardiac medications examined. Subgroup analysis also showed improvement in discharge prescriptions for P2Y12 inhibitors in patients who underwent a percutaneous coronary intervention. Presence of a do-not-resuscitate order, before co-morbidities, hospitalization for non-ST-segment elevation myocardial infarction, admission to a nonteaching hospital, and failure to undergo cardiac catheterization or a percutaneous coronary intervention were associated with underuse of CMT. In conclusion, our study demonstrates encouraging trends in the prescribing of evidence-based medications at hospital discharge for AMI. However, certain patient subgroups continue to be at risk for underuse of CMT, suggesting the need for strategies to enhance compliance with current practice guidelines. Copyright Â
© 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27743577      PMCID: PMC5651991          DOI: 10.1016/j.amjcard.2016.08.065

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  30 in total

1.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

2.  Guideline adherence after ST-segment elevation versus non-ST segment elevation myocardial infarction.

Authors:  Keith A Somma; Deepak L Bhatt; Gregg C Fonarow; Christopher P Cannon; Margueritte Cox; Warren Laskey; W Frank Peacock; Adrian F Hernandez; Eric D Peterson; Lee Schwamm; Leslie A Saxon
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2012-09-04

3.  Quality of care by classification of myocardial infarction: treatment patterns for ST-segment elevation vs non-ST-segment elevation myocardial infarction.

Authors:  Matthew T Roe; Lori S Parsons; Charles V Pollack; John G Canto; Hal V Barron; Nathan R Every; William J Rogers; Eric D Peterson
Journal:  Arch Intern Med       Date:  2005-07-25

4.  Full coverage for preventive medications after myocardial infarction.

Authors:  Niteesh K Choudhry; Jerry Avorn; Robert J Glynn; Elliott M Antman; Sebastian Schneeweiss; Michele Toscano; Lonny Reisman; Joaquim Fernandes; Claire Spettell; Joy L Lee; Raisa Levin; Troyen Brennan; William H Shrank
Journal:  N Engl J Med       Date:  2011-11-14       Impact factor: 91.245

5.  Temporal trends in the treatment of over 1.5 million patients with myocardial infarction in the US from 1990 through 1999: the National Registry of Myocardial Infarction 1, 2 and 3.

Authors:  W J Rogers; J G Canto; C T Lambrew; A J Tiefenbrunn; B Kinkaid; D A Shoultz; P D Frederick; N Every
Journal:  J Am Coll Cardiol       Date:  2000-12       Impact factor: 24.094

6.  Thirty-year trends (1975 to 2005) in the magnitude of, management of, and hospital death rates associated with cardiogenic shock in patients with acute myocardial infarction: a population-based perspective.

Authors:  Robert J Goldberg; Frederick A Spencer; Joel M Gore; Darleen Lessard; Jorge Yarzebski
Journal:  Circulation       Date:  2009-02-23       Impact factor: 29.690

7.  Trends in atrial fibrillation in patients hospitalized with an acute coronary syndrome.

Authors:  David D McManus; Wei Huang; Kunal V Domakonda; Jeanine Ward; Jane S Saczysnki; Joel M Gore; Robert J Goldberg
Journal:  Am J Med       Date:  2012-11       Impact factor: 4.965

8.  A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents.

Authors:  A Schömig; F J Neumann; A Kastrati; H Schühlen; R Blasini; M Hadamitzky; H Walter; E M Zitzmann-Roth; G Richardt; E Alt; C Schmitt; K Ulm
Journal:  N Engl J Med       Date:  1996-04-25       Impact factor: 91.245

9.  Recent changes in attack and survival rates of acute myocardial infarction (1975 through 1981). The Worcester Heart Attack Study.

Authors:  R J Goldberg; J M Gore; J S Alpert; J E Dalen
Journal:  JAMA       Date:  1986 May 23-30       Impact factor: 56.272

10.  Increasing use of single and combination medical therapy in patients hospitalized for acute myocardial infarction in the 21st century: a multinational perspective.

Authors:  Robert J Goldberg; Frederick A Spencer; Philippe Gabriel Steg; Marcus Flather; Gilles Montalescot; Enrique P Gurfinkel; Brian M Kennelly; Shaun G Goodman; Rebecca Dedrick; Joel M Gore
Journal:  Arch Intern Med       Date:  2007-09-10
View more
  10 in total

1.  Lipid-Lowering Prescription Patterns in Patients With Diabetes Mellitus or Cardiovascular Disease.

Authors:  Alanna M Chamberlain; Sarah S Cohen; Jill M Killian; Keri L Monda; Susan A Weston; Ted Okerson
Journal:  Am J Cardiol       Date:  2019-07-15       Impact factor: 2.778

2.  Are We Optimizing the Use of Dual Antiplatelet Therapy in Patients Hospitalized with Acute Myocardial Infarction?

Authors:  Essa Hariri; Darleen Lessard; Joel Gore; Jeffrey Rade; Robert Goldberg
Journal:  Cardiovasc Revasc Med       Date:  2019-05-02

3.  Implementation of a Cardiogenic Shock Team and Clinical Outcomes (INOVA-SHOCK Registry): Observational and Retrospective Study.

Authors:  Alexander Truesdell; Behnam Tehrani; Ramesh Singh; Charles Murphy; Patricia Saulino
Journal:  JMIR Res Protoc       Date:  2018-06-28

4.  Impact of cardiac- and noncardiac-related conditions on adverse outcomes in patients hospitalized with acute myocardial infarction.

Authors:  Mayra Tisminetzky; Jerry H Gurwitz; Ruben Miozzo; Joel M Gore; Darleen Lessard; Jorge Yarzebski; Robert J Goldberg
Journal:  J Comorb       Date:  2019-05-28

5.  PCSK9 Inhibitor Use in the Real World: Data From the National Patient-Centered Research Network.

Authors:  Alanna M Chamberlain; Yan Gong; Kathryn McAuliffe Shaw; Jiang Bian; Wen-Liang Song; MacRae F Linton; Vivian Fonseca; Eboni Price-Haywood; Emily Guhl; Jordan B King; Rashmee U Shah; Jon Puro; Elizabeth Shenkman; Pamala A Pawloski; Karen L Margolis; Adrian F Hernandez; Rhonda M Cooper-DeHoff
Journal:  J Am Heart Assoc       Date:  2019-05-07       Impact factor: 5.501

6.  Twenty-Year Trends in Outcomes for Older Adults With Acute Myocardial Infarction in the United States.

Authors:  Harlan M Krumholz; Sharon-Lise T Normand; Yun Wang
Journal:  JAMA Netw Open       Date:  2019-03-01

7.  Prescription Rates for Antiplatelet Therapy (APT) in Coronary Artery Disease (CAD) - What Benchmark are We Aiming at in Continuing Medical Education (CME)?

Authors:  Bernd Hagen; Reinhard Griebenow
Journal:  J Eur CME       Date:  2020-10-23

8.  Implementation of clinical audit to improve adherence to guideline-recommended therapy in acute coronary syndrome.

Authors:  Nimmy Elizabeth George; Aashiq Ahamed Shukkoor; Noel Joseph; Ramasamy Palanimuthu; Tamilarasu Kaliappan; Rajendiran Gopalan
Journal:  Egypt Heart J       Date:  2022-01-12

9.  Trends and variations in the prescribing of secondary preventative cardiovascular therapies for non-ST elevation myocardial infarction (NSTEMI) in Malaysia.

Authors:  Padmaa Venkatason; Nur Lisa Zaharan; Muhammad Dzafir Ismail; Wan Azman Wan Ahmad; Ahmad Syadi Mahmood Zuhdi
Journal:  Eur J Clin Pharmacol       Date:  2018-03-26       Impact factor: 2.953

10.  Outcomes in CME/CPD - Special Collection: How to make the "pyramid" a perpetuum mobile.

Authors:  Reinhard Griebenow; Peter Mills; Jörg Stein; Henrik Herrmann; Malte Kelm; Craig Campbell; Robert Schäfer
Journal:  J Eur CME       Date:  2020-10-27
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.